Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Lumos Diagnostics targets key US approvals for FebriDx test - ASX SMIDcaps

Lumos Diagnostics targets key US approvals for FebriDx test - ASX SMIDcaps

Lumos Diagnostics CFO Barrie Lambert joins Proactive's Fouad Haidar live from the ASX Small and Mid Cap Conference. Lumos specialises in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions.

Lumos offers customised assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercialises proprietary, Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK